Results 131 to 140 of about 283,519 (305)

Pharmacological regulation of the activity of cytochrome P450 3A4 AND P450 2C9 isoenzymes by vitamins and natural compounds

open access: yesРегуляторные исследования и экспертиза лекарственных средств, 2018
The influence of vitamins with antioxidant properties (vitamins A, E, C), B vitamins (B1, B2, B6) and vitamin-like substances (coenzyme Q10, taurine and L-carnitine) on the enzymes of the first phase of xenobiotic metabolism - cytochromes P450 3A4 and ...
E. V. Shikh   +3 more
doaj  

Early clinical pharmacology evaluation of the novel anti‐inflammatory macrolide, glasmacinal (EP395): tolerability, pharmacokinetics and drug interactions

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims This work assessed the pharmacokinetics (PK), safety and tolerability of glasmacinal (EP395, an oral anti‐inflammatory macrolide with negligible antimicrobial activity in development for COPD treatment) in two healthy participant trials: ‘first‐in‐human’ (FIH) and ‘drug–drug‐interaction’ (DDI).
Dave Singh   +5 more
wiley   +1 more source

Quantitative prediction of intravenous drug interactions caused by cytochromes P450 inhibitors and inducers

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Background Aims Pharmacokinetic interaction studies typically focus on oral administration, but intravenous (IV) administration bypasses intestinal degradation and hepatic first‐pass metabolism, leading to distinct drug–drug interaction (DDI) magnitude. This study aimed to develop a predictive model for DDIs involving IV‐administered drugs.
Vianney Tuloup   +2 more
wiley   +1 more source

Contraindicated drug–drug interactions and associated adverse drug reactions in an observational cohort study of 4543 paediatric hospitalized patients

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Background and Purpose Drug–drug interactions (DDIs) are associated with an increased risk of adverse drug reactions (ADRs). Hospitalized children are particularly vulnerable to DDIs and ADRs due to polypharmacy, frequent use of unlicensed or off‐label medications, and dosing regimens often extrapolated from adult data.
Emilie Laval   +6 more
wiley   +1 more source

HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Carbamazepine is licensed in the United Kingdom for the treatment of epilepsy, bipolar disorder and trigeminal neuralgia. The related compounds oxcarbazepine and eslicarbazepine are licensed for the treatment of epilepsy. These drugs can cause immune‐mediated hypersensitivity reactions, which typically affect the skin, and can be of variable severity ...
Lucy Galloway   +24 more
wiley   +1 more source

Physiologically‐based pharmacokinetic modelling of uridine 5′‐diphosphoglucorosultransferase (UGT) substrate drugs in pregnant women

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims While pregnancy‐related changes in phase I enzyme activity are well‐documented, less is known about the impact on phase II enzymes. This study aimed to test the hypothesis that changes in the pharmacokinetics (PK) of uridine 5′‐diphosphoglucuronosyltransferase (UGT) substrates during pregnancy result from altered enzyme expression or activity ...
William Saffaf   +6 more
wiley   +1 more source

The nitrite anion: the key intermediate in alkyl nitrates degradative mechanism. [PDF]

open access: yes, 2007
Alkyl nitrates, _in vivo_, are metabolized to yield nitric oxide, and thiol groups are considered necessary cofactors. This statement is based on studies that underline how these species potentiate hemodynamic responsiveness to nitrates in patients with ...
Loris Grossi
core   +1 more source

Endogenous melatonin partial metabolic clearance as a potential endogenous marker of CYP1A2 activity

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Cytochrome P450 1A2 (CYP1A2) exhibits substantial interindividual variability, necessitating appropriate phenotyping strategies for personalized pharmacotherapy. This study evaluated endogenous melatonin partial metabolic clearance (CLm(MEL)), calculated from urinary 6‐hydroxymelatonin (6‐O‐MEL) excretion and plasma melatonin (MEL) exposure, as a ...
Akitomo Yokokawa   +5 more
wiley   +1 more source

Hole migration in cytochrome P450

open access: yesQRB Discovery
The cytochrome P450 enzymes catalyze the hydroxylation of organic substrates by dioxygen. The high-potential reactive intermediate in cytochrome P450 catalysis, compound I (CI), has the capacity to deliver oxidizing equivalents (holes) to the side chains
Harry Gray, Jay Winkler
doaj   +1 more source

Optimal dosing for vascular anomalies paediatric patients with population pharmacokinetic model of sirolimus

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Sirolimus is currently used off‐label for paediatric patients with vascular anomalies. However, the optimal dosage regimen for paediatric patients remains controversial. This study aimed to determine the optimal dosing regimen of sirolimus in these patients using a population pharmacokinetic (PK) model.
Seongmee Jeong   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy